about
Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion.EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cellsDesign, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.Melanoma: clinical features and genomic insights.Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapyEmerging strategies for EphA2 receptor targeting for cancer therapeutics.EphA2 is a critical oncogene in melanoma.A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptorsEph/ephrin signaling in epidermal differentiation and diseaseIrradiation affects cellular properties and Eph receptor expression in human melanoma cells.EphA2 is a functional receptor for the growth factor progranulin.Recent progress in understanding the pathology of malignant melanoma.Receptor tyrosine kinases and their activation in melanoma.Vasculogenic mimicry: a novel target for glioma therapy.Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.Advanced research on vasculogenic mimicry in cancerRadiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2.Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo.Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma.EphA receptors regulate prostate cancer cell dissemination through Vav2-RhoA mediated cell-cell repulsion.Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 ReceptorThe EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells.Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis.
P2860
Q24300682-C9E103B0-950E-4B72-9701-846346E9659BQ30539320-A62F233E-7417-429E-B942-4B6CF8245D83Q33778507-6D8CF6B1-99EC-4482-9181-CAA205FF4EC4Q33848124-E4AEF64B-343A-4A0D-932F-73C624974334Q34083191-4CE106D7-E557-44E0-98E9-9ED82E6078CCQ34391376-79A4AE1F-F784-429A-9126-7F90BFD5E801Q34469271-DF1F3879-5E35-4DF6-B514-31739A9AC5DCQ35218960-5D866113-A877-42BA-B30F-8FCAED798717Q35385982-B0658DBE-BC83-4885-8F77-EA2BF0F75489Q36045304-5B773F46-94E7-48B2-BCDA-D03743EFEB61Q36402715-262B72EB-99A4-4845-8268-C2C76D36D985Q37488302-3D904402-01A1-40AA-AC2F-5DAA7617E7B0Q37601396-4B1A2C0F-CD55-4151-8AD5-95C65D5C8441Q37841746-D9EBBDC6-C6F7-4A87-93A5-97D73DF48697Q38118466-A7FF23C2-68FD-4440-827E-8BE5C29639BDQ38209232-A61F9DE6-95C2-48ED-8298-7622F4FF966BQ38322795-5D5932B1-E9AE-4C00-AB7B-17BC0C51D189Q38952546-DE878C8E-92C3-4D58-BC9B-A4F17F19E98BQ39442560-4012BCB8-0826-4155-ACE9-774304278B6FQ40365068-0FF129F5-FEFC-4880-86CE-327FCBEFE3E0Q40722621-2F0C21D3-2777-4645-A8DD-95DFEC0F866BQ41915374-6A31BFAC-9BAD-47F3-A752-1E114F2A8D21Q42110684-E4A40D36-88EF-4CF8-8415-92A09C66C328Q47143187-8E83EA3E-CBE7-4E22-ACA7-57F98D20F896Q47638547-A01ADD04-156B-4DE8-BE8B-958D3B2930AEQ51749008-278DA726-AF88-43D0-B83D-0A7C7F9406B4Q53168767-6BCD5FCD-7AC1-4164-9752-4DFFA1901A0D
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
EphA2 as a promoter of melanoma tumorigenicity
@ast
EphA2 as a promoter of melanoma tumorigenicity
@en
type
label
EphA2 as a promoter of melanoma tumorigenicity
@ast
EphA2 as a promoter of melanoma tumorigenicity
@en
prefLabel
EphA2 as a promoter of melanoma tumorigenicity
@ast
EphA2 as a promoter of melanoma tumorigenicity
@en
P2093
P2860
P356
P1476
EphA2 as a promoter of melanoma tumorigenicity
@en
P2093
Angela R Hess
Daniel E Abbott
Elisabeth A Seftor
Luigi Strizzi
M Sambasiva Rao
Mary J C Hendrix
Naira V Margaryan
P2860
P304
P356
10.4161/CBT.8.3.7485
P577
2009-02-21T00:00:00Z